Form 6-K ASTRAZENECA PLC For: Dec 16
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2016
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
16 December 2016 13:00
Transaction by a Person Discharging Managerial
Responsibilities
Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse
Regulation
On 16
December 2016, Pascal Soriot, a Director of the Company, notified
us that, on 16 December 2016, he ceased to be beneficially
interested in 59,951 AstraZeneca PLC Ordinary Shares of $0.25 each
as a result of a gift of those shares to family members for nil
consideration.
The
attached notification, made in accordance with the requirements of
the EU Market Abuse Regulation, gives further detail.
Notification
and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with
them
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
a)
|
Name
|
Pascal
Soriot
|
|
2
|
Reason for the notification
|
||
a)
|
Position/status
|
Chief
Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
Not
applicable
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Gift of
shares to family members for nil consideration
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
59,951
|
||
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
16
December 2016
|
|
f)
|
Place of the transaction
|
London
|
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media
Enquiries
|
|
|
Neil
Burrows
|
UK/Global
|
+44 203
749 5637
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
Christer
Gruvris
|
Autoimmunity,
neuroscience & infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
16 December 2016
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) PT Lowered to $84 at Morgan Stanley
- Biceps Coin Introduces Bitcoin Earning Potential for $BICS Token Holders
- Shippeo Spring Platform Release Reveals All-new Parcel Tracking, Advanced Carbon Emissions Monitoring Features, and Enhanced Container Tracking Data Quality
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!